
Treatment for severe form of epilepsy approved in Europe
UCB’s Fintepla (fenfluramine) oral solution has been recommended for marketing authorisation in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare, severe form of epilepsy. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion… Read More





